


SL-04. Oncology Phenotypic Screening

Deregulation of the balance between cell proliferation and death can lead to the formation of tumor malignancies. Signaling transduction pathways can regulate this process via the interaction of multiple functional extracellular and intracellular proteins such as kinases (e.g. EGFR, VEGF, Aurora A). Targeting these proteins leads to cytotoxic activity against various cells of tumor origin.

The ASINEX oncology-oriented phenotypic library includes compounds based on several scaffolds with proven cytotoxicity (sub- μM EC_{50} in MTT assay) against a number of

cancer cell lines: MV-411 (acute monocytic leukemia), HCT-116 (human colon cancer), MCF-7 (human breast adenocarcinoma), A-172 (Human glioblastoma), COLO-320 (colorectal adenocarcinoma), U-937 (histiocytic lymphoma), A-375 (malignant melanoma), BXPC-3 (pancreas adenocarcinoma), U118-MG (malignant glioma), and LN-229 (glioblastoma). Some active compounds were screened in a biochemical assay showing nM level of IC_{50} against several kinases: Aurora A, Haspin, VEGFR, EGFR, PDGFR.



Signature Library 04

Formats	Supplementary Information
80 compounds per plate 0.1 mg; 1 mg; 2 mg dry film/powder 0.1 μmol ; 1 μmol DMSO solutions	EC_{50} MTT test Solubility data in PBS SL#4_MTT_04-16.sdf

Contact us:

USA: +1 336 721 1617
Japan: +81-80-3401-9097
Europe/Global:

mparisi@asinex.com
sota@asinex.com
lsadovenko@asinex.com